Stiefel Laboratories, Inc.

Sterling Drug Inc.

Adora Animal Health Corporation

Schering-plough Healthcare Products Inc.

Chemapotheca, LLC

Pharmapotheca A, Inc.

Korb Research, Llc.

Other

Pharmapotheca, LLC

Mical Pharmaceuticals Llc—h Series, A Series Of Mical Pharmaceuticals Llc, A Multi-Division Limited Liability Company

Mical Pharmaceuticals LLC - H Series

Karl F Popp

Donald R Korb

Keith A Johnson

Harold Meckler

William G Gorman

David J Fairfax

John Quinn

Thomas Edward D'ambra

Thomas Michael Vaughn

Edward Richard Yuhas

John A Shipps

Keith Johnson

Werner K Stiefel

Kathleen L Clark

David M Sedlock

Samuel J Alioto

Brent D Stiefel

Jennifer C Galloway

Kenneth M Mavica

Joshua Alan Harrison

One aspect of the present application relates to a storage stable pharmaceutical composition comprising a sulfated glycosaminoglycan having an average molecular weight ranging from 3,000 to 15,000 Daltons, and a pharmaceutical carrier, where the pharmaceutical carrier is mixed with the sulfated glycosaminoglycan, as well as this composition's use in a method of treating a subject for a medically observable improvement. Another aspect of the present application relates to a process for producing a storage stable purified sulfated glycosaminoglycan.

Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions

The invention also relates to processes for producing abuse deterrent pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms

The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms

A substantially water-free ocular treatment composition including about 20% to about 45% beeswax and about 20% to about 45% jojoba oil. The composition can include at least one additional surfactant ingredient. The composition can be administered to a patient to improve the functionality of the tear film and decrease dry eye symptoms. The composition can be a semi-solid at room temperature and can liquefy when contacted with the skin at body temperature.

Ocular treatment compositions and methods of use thereof

A substantially water-free ocular treatment composition including about 20% to about 45% beeswax and about 20% to about 45% jojoba oil. The composition can include at least one ingredient selected from the group consisting of shea butter, caprylic/capric triglyceride, phospholipid, sodium hyaluronate, and coconut oil. The composition can be administered to a patient to improve the functionality of the tear film and decrease dry eye symptoms. The composition can be a semi-solid at room temperature and can liquefy when contacted with the skin at body temperature.

Storage stable, topical lotion compositions for treating corticosteroid-responsive dermatoses are provided by the present invention which include a halobetasol material comprising halobetasol or its pharmaceutically acceptable salts, esters, and solvates; and a pharmaceutically acceptable carrier which includes: (a) one or more fatty alcohols and/or one or more alkoxylated fatty alcohols, (b) one or more polyol humectants, and (c) diisopropyl adipate. Storage stable, topical lotion compositions for treating corticosteroid-responsive dermatoses are provided by the present invention which include 0.05% halobetasol propionate; and a pharmaceutically acceptable carrier which includes: (a) one or more fatty alcohols and/or one or more alkoxylated fatty alcohols, (b) one or more polyol humectants, and (c) diisopropyl adipate.

Topical steroid composition and method

Novel compositions of matter comprising a foamable delivery system are provided. Novel methods for treating a disease, disorder, or condition using the novel compositions are further provided. Novel methods for making and delivering a foamable pharmaceutical composition are also provided. While the novel compositions and foamable drug delivery system may be utilized for administration of a wide variety of drugs to epithelial tissues, to treat a wide variety of diseases, disorders, or conditions, the inventive compositions and foamable drug delivery systems are particularly useful for the dermatological administration of corticosteroids and antifungal agents.

Foamable pharmaceutical compositions and methods for treating a disorder

A composition for treatment of hyperpigmentation having a SPF value of at least 15 includes hydroquinone, sunscreens, antioxidants and emulsifiers and emollients. The composition can be made into an emulsion having physical and chemical stability for a prolonged period of time over a wide range of temperatures.

Compositions for treatment of hyperpigmentation and methods for making and using such compositions

A dietary supplement composition for promoting healthy skin comprised of lycopene and other carotenoids, selenium, chromium and biotin.

Dietary supplement composition and method for improving and maintaining healthy skin

The present invention is directed towards a topical composition for the treatment of acne comprising water, an organic peroxide, an alpha hydroxy acid, a moisturizer, an isosorbide and a detergent. This invention also is directed to a method of making the composition of this invention. The method involves (1) heating water to between 60&deg; C. and 70&deg; C.; (2) adding a detergent base to the water and mixing the solution; (3) cooling the solution and adding an alpha hydroxy acid, an isosorbide and sodium pyrollidone carboxylate; (4) continuing to cool the solution to between 25&deg; C. and 35&deg; C. and then adding benzoyl peroxide and a preservative to the solution; (5) mixing and milling the product until smooth; and (6) adjusting the pH of the product to a pH of 3-5 with a base. This invention also is directed towards a method for treating a patient afflicted with acne by applying the composition of this invention to the affected areas of the patient's skin.

Topical anti-acne composition

Gel film-forming flexible collodion compositions can be improved by including one or more topically acceptable polymers in an amount sufficient to increase the resilience of the film formed. Suitable polymers include polyalkylenes and (meth)acrylate homo- or copolymers. The compositions can further include salicylic acid and a topically acceptable crystallization inhibitor in an amount sufficient to suppress the crystallization of dissolved salicylic acid from the composition.

Growing community of inventors

Schodack Landing, NY, United States of America

Karl F Popp